ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$234.56Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $30,358,396,928.00
EPSttm : -2.18
Alnylam Pharmaceuticals, Inc.
$234.56
1.76%$4.06Float Short %
2.4
Margin Of Safety %
Put/Call OI Ratio
0.64
EPS Next Q Diff
0.42
EPS Last/This Y
2.99
EPS This/Next Y
2.86
Price
234.56
Target Price
318.89
Analyst Recom
1.74
Performance Q
-5.86
Relative Volume
0.67
Beta
0.24
Ticker: ALNY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-21 | ALNY | 283.08 | 0.74 | 0.49 | 21867 |
| 2025-03-24 | ALNY | 290.61 | 0.71 | 0.64 | 17583 |
| 2025-03-25 | ALNY | 280.91 | 0.71 | 0.73 | 20828 |
| 2025-03-26 | ALNY | 269.14 | 0.70 | 1.21 | 20694 |
| 2025-03-27 | ALNY | 270.84 | 0.71 | 0.16 | 21200 |
| 2025-03-28 | ALNY | 268.35 | 0.70 | 0.75 | 21393 |
| 2025-03-31 | ALNY | 270.22 | 0.71 | 1.45 | 21553 |
| 2025-04-01 | ALNY | 256.95 | 0.73 | 1.96 | 21805 |
| 2025-04-02 | ALNY | 267.03 | 0.75 | 0.35 | 22118 |
| 2025-04-03 | ALNY | 262.41 | 0.73 | 0.74 | 22615 |
| 2025-04-04 | ALNY | 235.58 | 0.73 | 0.35 | 23432 |
| 2025-04-07 | ALNY | 232.85 | 0.68 | 1.06 | 24692 |
| 2025-04-08 | ALNY | 224.5 | 0.67 | 1.61 | 24586 |
| 2025-04-09 | ALNY | 242.88 | 0.68 | 0.82 | 24971 |
| 2025-04-10 | ALNY | 225.86 | 0.68 | 1.50 | 25169 |
| 2025-04-11 | ALNY | 237.6 | 0.68 | 3.00 | 25635 |
| 2025-04-14 | ALNY | 239.94 | 0.69 | 0.47 | 25977 |
| 2025-04-15 | ALNY | 230.6 | 0.69 | 3.09 | 26946 |
| 2025-04-16 | ALNY | 230.48 | 0.65 | 1.47 | 26392 |
| 2025-04-17 | ALNY | 234.47 | 0.64 | 0.16 | 26316 |
| 2025-04-18 | ALNY | 234.56 | 0.64 | 0.19 | 26316 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-21 | ALNY | 283.43 | -161.2 | 189.1 | 0.52 |
| 2025-03-24 | ALNY | 290.70 | -146.4 | 193.1 | 0.52 |
| 2025-03-25 | ALNY | 280.96 | -146.4 | 195.6 | 0.71 |
| 2025-03-26 | ALNY | 269.21 | -147.0 | 196.6 | 0.83 |
| 2025-03-27 | ALNY | 270.92 | -147.0 | 194.6 | 0.83 |
| 2025-03-28 | ALNY | 268.46 | -147.0 | 195.3 | 0.83 |
| 2025-03-31 | ALNY | 270.02 | -147.0 | 194.6 | 0.83 |
| 2025-04-01 | ALNY | 255.76 | -147.0 | 197.1 | 0.83 |
| 2025-04-02 | ALNY | 266.83 | -147.0 | 193.0 | 0.82 |
| 2025-04-03 | ALNY | 262.35 | -147.0 | 195.6 | 0.82 |
| 2025-04-04 | ALNY | 235.61 | -147.0 | 199.1 | 0.82 |
| 2025-04-07 | ALNY | 232.94 | -124.1 | 195.3 | 0.96 |
| 2025-04-08 | ALNY | 224.32 | -124.1 | 196.4 | 0.83 |
| 2025-04-09 | ALNY | 243.05 | -124.1 | 191.3 | 0.83 |
| 2025-04-10 | ALNY | 225.87 | -124.1 | 197.9 | 0.83 |
| 2025-04-11 | ALNY | 237.61 | -124.1 | 192.6 | 0.83 |
| 2025-04-14 | ALNY | 240.01 | -124.1 | 194.5 | 0.83 |
| 2025-04-15 | ALNY | 230.93 | -115.3 | 196.5 | 0.81 |
| 2025-04-16 | ALNY | 230.49 | -115.3 | 194.9 | 0.81 |
| 2025-04-17 | ALNY | 234.56 | -115.3 | 194.1 | 0.81 |
| 2025-04-18 | ALNY | 234.56 | -115.3 | 194.9 | 0.81 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-21 | ALNY | -1.76 | -0.30 | 2.01 |
| 2025-03-24 | ALNY | -1.76 | -0.26 | 2.01 |
| 2025-03-25 | ALNY | -2.05 | -0.26 | 2.01 |
| 2025-03-26 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-03-27 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-03-28 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-03-31 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-01 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-02 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-03 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-04 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-07 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-08 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-09 | ALNY | -2.05 | -0.26 | 2.04 |
| 2025-04-10 | ALNY | -2.05 | -0.26 | 2.40 |
| 2025-04-11 | ALNY | -2.05 | -0.26 | 2.40 |
| 2025-04-14 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-15 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-16 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-17 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-18 | ALNY | -2.05 | -0.09 | 2.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.65
Avg. EPS Est. Current Quarter
-0.4
Avg. EPS Est. Next Quarter
-0.23
Insider Transactions
-2.05
Institutional Transactions
-0.09
Beta
0.24
Average Sales Estimate Current Quarter
584
Average Sales Estimate Next Quarter
632
Fair Value
Quality Score
45
Growth Score
54
Sentiment Score
64
Actual DrawDown %
22.9
Max Drawdown 5-Year %
-42.5
Target Price
318.89
P/E
Forward P/E
154.46
PEG
P/S
13.57
P/B
452.05
P/Free Cash Flow
EPS
-2.17
Average EPS Est. Cur. Y
0.81
EPS Next Y. (Est.)
3.67
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-12.37
Relative Volume
0.67
Return on Equity vs Sector %
-434.6
Return on Equity vs Industry %
-421.2
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
0.29
EBIT Estimation
194.9
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading